A systematic review of dydrogesterone for the treatment of recurrent miscarriage

References

• Salat-Baroux J. Recurrent spontaneous abortions. Reprod Nutr Dev 1988;28:1555–68
   PubMedGoogle Scholar
• Hameed A, Malik S, Regan L. Should progestogen supplementation be used? No. In: Carp HJA, ed. Recurrent pregnancy loss, causes, controversies and treatment. 2nd ed. London: CRC Press; 2014:131–5
   Google Scholar
• Check J. Should progestogen supplementation be used? Yes. In: Carp HJA, ed. Recurrent pregnancy loss, causes, controversies and treatment. 2nd ed. London: CRC Press; 2014:123–9
   Google Scholar
• Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96:275–80
   PubMedGoogle Scholar
• Le Vine L. Habitual abortion. A controlled study of progestational therapy. West J Surg Obstet Gynecol 1964;72:30–6
   PubMedGoogle Scholar
• Swyer GIM, Daley D. Progesterone implantation in habitual abortion. Brit Med J 1953;I:1073–7
   Google Scholar
• Goldzieher JW. Double-blind trial of a progestin in habitual abortion. JAMA 1964;188:651–4
   PubMed Web of Science ®Google Scholar
• Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003;(4):CD003511
   PubMedGoogle Scholar
• El Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005;97:431–4
   PubMedGoogle Scholar
• Kumar A, Begum N, Prasad S, et al. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 2014;102:1357–63
   Google Scholar
• Freedman RS. Progesterone defficiency in Pregnancy. S Afr Med J 1970;44:72–6
   Google Scholar
• Walch K, Hefler L, Nagele F. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial. J Matern Fetal Neonatal Med 2005;18:265–9
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Barakonyi A, Polgar B, et al. The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 1999;42:44–8
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Makhseed M, Azizieh F, et al. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000;15:713–18
   PubMed Web of Science ®Google Scholar
• Arck PC, Rücke M, Rose M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–13
   PubMed Web of Science ®Google Scholar
• Ghosh S, Chattopadhyay R, Goswami S, et al. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res 2014;40:1871–6
   PubMed Web of Science ®Google Scholar
• Stovall TG, Ling FW, Carson SA, Buster JE. Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy. Fertil Steril 1992;57:456–7
   PubMed Web of Science ®Google Scholar
• Al-Sebai MA, Kingsland CR, Diver M, et al. The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Br J Obstet Gynaecol 1995;102:364–9
   PubMedGoogle Scholar
• Chang IW. Clinical trial of isopregnenone, a new progestational agent. Med Ann Dist Colomb 1962;31:402–6
   PubMedGoogle Scholar
• Lopez Lopez E, Gonzales E, Noguera MC, et al. Luteal phase defect and habitual abortion: therapy and results (article in Spanish). Acta Ginecol 1988;14:72–5
   Google Scholar
• Aydar CK, Greenblatt RB. 6-dehydro-retroprogesterone (duphaston) an interesting progesterone-like compound. Int J Fertil 1964;9:585–95
   PubMedGoogle Scholar
• Backer MH. Isopregnenone (Duphaston): a new progestational agent. Obstet Gynecol 1962;19:724–9
   PubMedGoogle Scholar
• Gellé P, Schaeffer P. Apropos of the use of dydrogesterone in gynecology and obstetrics; clinical experience. Bull Fed Soc Gynecol Obstet Lang Fr 1965;17:369–70 [Article in French]
   PubMedGoogle Scholar
• Jamain M, Grenet C. Utilisation de la 6-déhydro-rétroprogestérone en obstétrique. Indications, résultats. J Soc Nat De Gyn Obstet De: France 1969;21:26–31 [Article in French]
   Google Scholar
• Sureau C, Combourieu P. Clinical study of 6-dehydro-retroprogesterone (dydrogesterone). Bull Fed Soc Gynecol Obstet Lang Fr 1964;16:263–9 [Article in French]
   PubMedGoogle Scholar
• MacDonald RR, Goulden R, Oakey RE. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstet Gynecol 1972;40:394–402
   PubMed Web of Science ®Google Scholar
• Balasch J, Creus M, Marquez M, et al. The significance of luteal phase defficiency on fertility: a diagnostic and therapeutic approach. Hum Reprod 1986;1:145–7
   PubMedGoogle Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011;12:CD005943
   PubMedGoogle Scholar
• Carp HJA. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983–90
   PubMed Web of Science ®Google Scholar
• Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 1997;85:375–7
   Google Scholar
• Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage: results from a UK-population-based case–control study. BJOG 2007;114:170–86
   PubMed Web of Science ®Google Scholar
• Gracia CR, Sammel MD, Chittams J, et al. Risk factors for spontaneous abortion in early symptomatic first-trimester pregnancies. Obstet Gynecol 2005;106:993–9
   PubMed Web of Science ®Google Scholar
• Achiron R, Tadmor O, Mashiach S. Heart rate as a predictor of first-trimester spontaneous abortion after ultrasound-proven viability. Obstet Gynecol 1991;78:330–4
   PubMed Web of Science ®Google Scholar
• Li TC, Makris M, Tomsu M, et al. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update 2002;8:463–81
   PubMed Web of Science ®Google Scholar
• Laufer MR, Ecker JL, Hill JA. Pregnancy outcome following ultrasound-detected fetal cardiac activity in women with a history of multiple spontaneous abortions. J Soc Gynecol Investig 1994;1:138–42
   PubMedGoogle Scholar
• Abraham GE, Maroulis GB, Marshall JR. Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone. Obstet Gynecol 1974;44:522–5
   PubMed Web of Science ®Google Scholar
• la Marca A, Morgante G, De Leo V. Human chorionic gonadotropin, thyroid function, and immunological indices in threatened abortion. Obstet Gynecol 1998;92:206–11
   PubMedGoogle Scholar
• Florio P, Luisi S, D’Antona D, et al. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril 2004;81:468–70
   PubMedGoogle Scholar
• Fiegler P, Katz M, Kaminski K, Rudol G. Clinical value of a single serum CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med 2003;48:982–8
   PubMed Web of Science ®Google Scholar
• Schmidt T, Rein DT, Foth D, et al. Prognostic value of repeated serum CA 125 measurements in first trimester pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;97:168–73
   PubMed Web of Science ®Google Scholar